Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | THPO | P40225 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565726 | 0.82 | CA12 (0.46) | LMNACXCR2GAAL3MBTL1KMT2A | |
| SCHEMBL6562115 | 0.81 | GSTO1 (0.43) | PKMCXCR2GAAL3MBTL1KMT2A | |
| SCHEMBL6563433 | 0.81 | VCAM1 (0.41) | LMNAPKMCXCR2L3MBTL1KMT2A | |
| SCHEMBL6565765 | 0.79 | VCAM1 (0.41) | LMNAPKMCXCR2GAAKMT2A | |
| SCHEMBL6565584 | 0.79 | CXCR2 (0.56) | LMNAPKMCXCR2GAARAB9A | |
| SCHEMBL6564241 | 0.79 | TSHR (0.50) | LMNAPKMCXCR2GAAKMT2A | |
| SCHEMBL27552122 | 0.77 | FABP4 (0.42) | CXCR2FABP4ALDH1A1CA1CA2 | |
| SCHEMBL6563454 | 0.77 | CXCR2 (0.44) | LMNACXCR2GAAL3MBTL1KMT2A | |
| SCHEMBL6563387 | 0.76 | CXCR2 (0.43) | LMNACXCR2GAARAB9AKMT2A | |
| SCHEMBL6563429 | 0.76 | CXCR1 (0.45) | CXCR2GAAKMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
| EP-1161232-A4 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1161232-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000035442-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | LMNA 4741/4885PKM 4143/4885CXCR2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.